ArticleCaspian journal of internal medicine2011
Efficacy of pentoxifylline for reduction of proteinuria in type II diabetic patients.
Article in Caspian journal of internal medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 4 syntheses or guidelines pooled it, 12 citations in OpenAlex.
- Antioxidants for adults with chronic kidney disease.The Cochrane database of systematic reviews · 2023Pooled it
- Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis.The Journal of international medical research · 2017Pooled it
- Effect of pentoxifylline in proteinuric chronic kidney disease: a systematic review and meta-analysis.Journal of nephrology · 2016Pooled it
- Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis.International urology and nephrology · 2015Pooled it
- Effects of Pentoxifylline on Serum Markers of Diabetic Nephropathy in Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022Article
- Targeting Inflammation in Diabetic Kidney Disease: Is There a Role for Pentoxifylline?Kidney360 · 2020Review
- Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update.Journal of biomedical science · 2017Review
- Diabetic nephropathy - complications and treatment.International journal of nephrology and renovascular disease · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic nephropathy is considered to be the most common cause of end stage renal disease (ESRD). Proteinuria is declared as the most marked risk factor in progression towards ESRD. The aim of this study was to evaluate the efficacy of pentoxifylline for reduction of proteinuria in type II diabetic patients.
methodsFrom May 2007 to June 2008, this randomized clinical trial study was performed on 60 type II diabetic patients with proteinuria over 500 mg/day despite receiving angiotensin receptor or angiotensin converting enzyme inhibitors. These patients were randomly divided into group A (Placebo) and group B (Pentoxifylline 400 mg 3 times daily). A twenty-four hour urine protein and creatinine clearance were assessed before and after three months of treatment.
resultsAmong the 56 patients, 38 were females and 18 were males. The mean age of patients in the placebo group was 57.6±9.3 and in the treatment group was 55.3±9.3 years. The duration of the disease in the placebo group was 14.03±5.7 and in the treated group was 11.9±6.2 years. The reduction of proteinuria in placebo group was 294±497 mg/dl and in the case group was 979±695 mg/dl (p<0.05). The mean creatinine clearance in placebo group was 79.4±19.9 and in the case group was 80.6± 22.8 mL/min (p>0.05).
conclusionThe results show that adding pentoxifylline to other approved angiotensin system inhibitors can significantly reduce proteinuria in diabetic nephropathy and influence progression of the disease with no effect on renal function.
Indexed as
Identifiers
24551437PMC3895828W276940052What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.